Announcements Trials
Browse Landscape

Phase

Phase 2 75Phase 1 41Phase 3 32Phase 1/2 21Phase 4 5Phase NA 4Phase EARLY_PHASE1 3Phase 2/3 2

Status

Completed 3Unknown 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 5Thyroid Neoplasms 1Patient Acceptance of Health Care 1Ovarian Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Letrozole 23Docetaxel 17Cyclophosphamide 13Zoledronic Acid 12Trastuzumab 12Anastrozole 12exemestane 11Tamoxifen 11Paclitaxel 11Capecitabine 10Fulvestrant 8Epirubicin 8pegfilgrastim 7Saline Solution 7Bupivacaine 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Sodium Chloride 6Filgrastim 6Carboplatin 6pegylated granulocyte colony-stimulating factor 5palbociclib 5Ropivacaine 5Dexmedetomidine 5Bevacizumab 5ribociclib 4eribulin 4Vinorelbine 4Tranexamic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 4 × palbociclib × Breast × Clear all
NCT07487129 2026-03-23

Clinical and P

Beni-Suef University

Phase 4 Completed
206 enrolled
Breast

Breast Neoplasms

NCT03355157 2024-10-01

PADMA

GBG Forschungs GmbH

Phase 4 Completed
130 enrolled
Breast

Breast Neoplasms, Patient Acceptance of Health Care

NCT05949424 2023-11-29

OPTI-DOSE

University Medical Center Groningen

Phase 4 Unknown
30 enrolled
BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT02679755 2022-07-27

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

Pfizer

Phase 4 Completed
252 enrolled 15 charts
Breast

Breast Neoplasms

NCT03220178 2022-01-06

PRECYCLE

Palleos Healthcare GmbH

Phase 4 Terminated
532 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡